Two de­cen­tral­ized tri­als star­tups prove they're not im­mune to broad­er wave of biotech lay­offs

Af­ter rais­ing heaps of cap­i­tal dur­ing the first two years of the Covid-19 pan­dem­ic to help bio­phar­mas shift to vir­tu­al clin­i­cal stud­ies, a few de­cen­tral­ized …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER